Century Therapeutics, Inc. Form 4 Filings

Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, sold 1,658 shares of common stock on September 14, 2026 at $1.93 per share. According to the company’s disclosure, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and Carr held 502,907 shares directly afterward.

Century Therapeutics, Inc. (IPSC) reported that President and CEO Brent Pfeiffenberger had 13,850 shares of common stock withheld on September 11, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. After this tax-withholding disposition, he beneficially holds 3,633,839 common shares directly. No Rule 10b5-1 trading plan is reported.

Century Therapeutics, Inc. (symbol: IPSC) is the issuer of record for a Form 4 filing submitted to the SEC. Truitt Joseph reported acquisition or exercise transactions in this Form 4 filing.

Century Therapeutics, Inc. (IPSC) reported that director Joseph Truitt received a grant of 148,000 stock options on September 9, 2026, each exercisable for one share of common stock at $2.03 per share and expiring on September 9, 2036. The options vest in equal monthly installments over 36 months, subject to his continued service to the company. Following this grant, he holds 148,000 options directly.

Century Therapeutics, Inc. (IPSC) reported that President and CEO Brent Pfeiffenberger had 463 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. This tax-withholding disposition was priced at $2.11 per share, and he now directly holds 3,633,839 common shares. No Rule 10b5-1 trading plan is reported for this transaction.

Century Therapeutics, Inc. (IPSC) reported that Chief Technology and Manufacturing Officer Gregory Russotti sold 534 shares of common stock on September 8, 2026 at $2.05 per share. A footnote states these shares were sold automatically to cover tax withholding obligations related to vesting restricted stock units and not at his discretion.

After this transaction, Russotti held 511,785 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for these transactions.

Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, had an automatic sale of 254 shares of common stock on September 8, 2026 at $2.05 per share. According to the footnote, the sale covered tax withholding obligations from vesting restricted stock units, was not discretionary, and left him holding 504,565 shares directly.

Century Therapeutics, Inc. (IPSC) reported an insider tax-related share disposition by President and CEO Brent Pfeiffenberger. On 2026-08-14, 31,172 shares of common stock were withheld by the company at $1.92 per share to satisfy tax withholding obligations upon vesting of restricted stock units. After this withholding, Pfeiffenberger directly holds 3,634,302 shares of Century Therapeutics common stock.

Century Therapeutics, Inc. senior vice president of Finance & Operations Douglas Carr reported selling 275 shares of common stock on August 3, 2026 at $1.977 per share. According to the footnote, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and were not sold at his discretion. Following the sale, Carr directly held 504819 shares of common stock.

Century Therapeutics, Inc. executive Gregory Russotti reported an automatic sale of shares to cover taxes on vested stock awards. On June 12, 2026, 2,584 shares of common stock were sold in open-market transactions at an average price of $2.232 per share to satisfy tax withholding obligations tied to restricted stock unit vesting. The filing explains these sales were automatic and not at Russotti’s discretion. After the sale, he directly held 512,319 common shares and indirectly held 92,773 shares through the Gregory Russotti 2021 Family Trust.

Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of common stock tied to tax withholding. On June 12, 2026, he sold 1,654 shares at $2.232 per share in an open-market transaction to cover taxes from restricted stock unit vesting.

These sales were executed automatically and not at his discretion, according to the disclosure. After the transaction, Carr still directly owns 505,094 shares of Century Therapeutics common stock, indicating he retains a substantial equity position in the company.

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 13,849 shares of Common Stock at $2.24 per share to satisfy tax withholding obligations. This was not an open-market sale, and Pfeiffenberger continues to hold 3,665,474 shares of Common Stock directly after the transaction.

Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported routine share activity related to equity compensation. On June 11, 2026, 358 shares of common stock were withheld at $2.24 per share to cover tax obligations upon the vesting of restricted stock units, which is not an open-market sale. After this tax-withholding disposition, Cowan directly holds 1,175,322 common shares. A separate entry reports 10,697 common shares held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except to any pecuniary interest.

Century Therapeutics director Alessandro Riva received a grant of stock options as compensation. The Form 4 shows an award of 74,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $2.24 per share.

The options expire on June 11, 2036 and vest on the earlier of June 11, 2027 or the next annual meeting of stockholders, in each case only if Riva continues in service through the vesting date. Following this grant, he holds 74,000 options directly.

Century Therapeutics director Daphne Quimi received a grant of stock options for 74,000 shares of Common Stock. The options have an exercise price of $2.24 per share, expire on June 11, 2036, and vest on the earlier of June 11, 2027, or the next annual stockholder meeting, subject to continued service. Following this grant, Quimi holds 74,000 stock options directly.

Century Therapeutics director Martin Patrick Murphy received a grant of stock options as part of his compensation. He was awarded options covering 74,000 shares of common stock at an exercise price of $2.24 per share, expiring on June 11, 2036.

The option vests on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to his continued service through the vesting date. Following this grant, he holds options for 74,000 shares directly, with no open-market buying or selling reported in this filing.

Century Therapeutics, Inc. reported that director Lee Han Myung received a grant of stock options covering 74,000 shares of common stock. The options have an exercise price of $2.24 per share and expire on June 11, 2036.

The option award vests on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, in each case only if Lee Han Myung continues to serve through the vesting date. Following this grant, the filing shows holdings of 74,000 stock options directly.

Century Therapeutics director Kimberly Blackwell received a stock option grant for 74,000 shares of common stock. The option has an exercise price of $2.24 per share and expires on June 11, 2036. All 74,000 options vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to her continued service.

Century Therapeutics, Inc. insider Gregory Russotti reported an automatic sale of shares to cover taxes on vesting stock awards. The Form 4 shows a sale of 524 shares of common stock at $2.111 per share, which a footnote explains was required to cover tax withholding obligations from vesting restricted stock units and was not at his discretion.

After this transaction, Russotti holds 514,903 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust, indicating the tax-related sale is small relative to his overall position.

Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic sale of 249 shares of common stock. The shares were sold on June 8, 2026 at $2.111 per share to cover tax withholding obligations tied to vesting restricted stock units. According to the filing, these sales were automatic and not at Carr’s discretion. After the transaction, he directly holds 506,748 shares of Century Therapeutics common stock.

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a small share disposition related to taxes. On the vesting of restricted stock units, 463 shares of Common Stock were withheld by the company at a price of $2.13 per share to cover tax withholding obligations, leaving him with 3,679,323 shares held directly.

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger had 31,172 shares of Common Stock withheld by the company to cover taxes tied to restricted stock units vesting. After this tax-withholding disposition, he holds 3,679,786 shares of Century Therapeutics Common Stock directly.

Century Therapeutics, Inc. Senior Vice President of Finance & Operations Douglas Carr completed an automatic sale of 264 shares of common stock at $2.341 per share. The sale was made solely to cover tax withholding obligations arising from the vesting of restricted stock units and was not at his discretion.

Following this tax-related sale, Carr directly holds 506,997 shares of Century Therapeutics common stock, indicating that the transaction represents a very small portion of his overall equity position.

Century Therapeutics, Inc. director Martin Patrick Murphy received a grant of stock options as equity compensation. The award covers 88,000 options for Common Stock with an exercise price of $0.592 per share, expiring on December 9, 2035.

The options were granted in connection with his appointment as a director and will vest in equal monthly installments over 36 months, conditioned on his continued service to the company. After this grant, he directly holds 88,000 stock options.

Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported a routine tax-related share withholding. On 2026-04-01, 1,365 shares of common stock were withheld at $2.19 per share to satisfy tax obligations from vesting restricted stock units, not an open-market sale.

After this transaction, Cowan directly held 1,175,680 shares of common stock. An additional 10,697 shares were held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.

Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of 7,043 shares of common stock at $2.549 per share on March 12, 2026. The filing describes this as an open-market transaction.

According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units and the sale was not at his discretion. After the transaction, Carr still directly holds 507,261 shares of Century Therapeutics common stock.

Century Therapeutics, Inc. officer Gregory Russotti reported an automatic sale of 10,076 shares of common stock at $2.549 per share. According to the filing, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units and were not sold at his discretion.

After the transaction, Russotti directly holds 515,427 common shares and indirectly holds 92,773 shares through the Gregory Russotti 2021 Family Trust. The activity reflects routine tax-related share withholding rather than a discretionary change in his investment position.

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a routine tax-related share disposition. The company withheld 55,397 shares of Common Stock at $2.73 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Pfeiffenberger directly holds 3,710,958 shares of Century Therapeutics common stock. This event reflects compensation-related tax settlement rather than an open-market stock sale.

Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported a routine tax-related share disposition. On March 11, 2026, 1,431 shares of common stock were withheld by the company at $2.73 per share to satisfy tax obligations tied to vesting restricted stock units, not an open-market sale. After this transaction, Cowan directly holds 1,177,045 shares of common stock. An additional 10,697 shares are held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.

Century Therapeutics, Inc. officer Gregory Russotti reported an automatic sale of 479 shares of common stock on March 9, 2026 at $2.536 per share. According to the footnote, this sale was executed solely to cover tax withholding obligations related to vesting restricted stock units and was not at his discretion.

After the transaction, Russotti directly held 525,503 common shares and also had an indirect holding of 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing therefore reflects a routine tax-related sale while maintaining a substantial ongoing equity position.

Century Therapeutics SVP Finance & Operations Douglas Carr reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 9, 2026, he sold 247 shares at $2.536 per share to cover tax obligations. After this transaction, he continued to hold 514,304 shares of Century Therapeutics common stock directly. The footnote explains these sales were required and not at his discretion, indicating a routine tax-related transaction rather than an active portfolio decision.

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, 463 shares of common stock were withheld by the company at $2.56 per share to satisfy tax withholding obligations. This was not an open-market sale. After this withholding, he directly holds 3,766,355 shares of Century Therapeutics common stock.

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On February 13, 2026, 31,172 shares of common stock were withheld by the company at $1.75 per share to satisfy tax obligations tied to restricted stock unit vesting. After this withholding, he directly owned 3,766,818 common shares.

Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic share sale linked to equity compensation. On February 3, 2026, he sold 323 shares of Common Stock at $1.822 per share to cover tax withholding obligations from vesting restricted stock units.

After this tax-related sale, Carr beneficially owned 514,551 shares of Century Therapeutics common stock, held directly. The filing explains that the transaction was executed automatically and was not made at his discretion.

Century Therapeutics President and CEO Brent Pfeiffenberger received new equity awards. On February 2, 2026, he was granted 475,000 shares of common stock in the form of restricted stock units at a price of $0 per share.

He also received a stock option for 945,000 shares of common stock at an exercise price of $1.84 per share. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over three years, while the option vests 25% on February 2, 2027 and the rest in 36 equal monthly installments, all subject to continued service.

Century Therapeutics, Inc. reported that Chief Technology and Manufacturing Officer Gregory Russotti received new equity awards. On February 2, 2026, he was granted 135,000 shares of common stock in the form of restricted stock units at $0 per share, increasing his directly held common stock to 525,982 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service.

Russotti was also granted a stock option for 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments thereafter. In addition, 92,773 shares of common stock are reported as indirectly owned through the Gregory Russotti 2021 Family Trust.

Century Therapeutics Chief Scientific Officer Chad Cowan received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 135,000 restricted stock units at no cash cost, increasing his directly held common stock to 1,178,476 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service. He was also granted a stock option covering 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments, also subject to continued service. Separately, 10,697 shares are held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.

Century Therapeutics reported that Douglas Carr, its SVP Finance & Operations, received equity awards. He was granted 110,000 restricted stock units, each representing one share of common stock, vesting 25% on February 2, 2027 and the remaining 75% quarterly over three years, subject to continued service.

He was also granted a stock option for 225,000 shares at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the remaining 75% in 36 equal monthly installments, expiring on February 2, 2036. After these grants, he beneficially owns 514,874 common shares directly and 225,000 options.

Century Therapeutics, Inc. reported an insider transaction by a director who also serves as President and CEO. On 12/12/2025, this person acquired 52,000 shares of common stock in a transaction coded “P” at a weighted average price of $0.5837 per share.

After this purchase, the insider beneficially owns 3,322,990 common shares with direct ownership. The filing notes that the shares were bought in multiple trades between $0.577 and $0.5838 per share, and that all profits from the reported transactions will be disgorged to the company under applicable requirements.

Century Therapeutics, Inc.'s president and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/10/2025, 463 shares of common stock were withheld at $0.526 per share to cover tax obligations triggered by the vesting of restricted stock units. After this transaction, the executive directly owns 3,270,990 shares of Century Therapeutics common stock.

Century Therapeutics (IPSC) Chief Scientific Officer reported an automatic sale of company stock related to tax withholding. On 11/20/2025, the reporting person sold 5,462 shares of common stock at $0.501 per share in a transaction labeled as a sale to cover tax obligations from vesting restricted stock units. After this transaction, the reporting person beneficially owned 987,027 shares directly and 10,697 shares indirectly through a trust. The filing notes that the trust-held shares are disclaimed as beneficially owned except to the extent of any pecuniary interest.

Century Therapeutics, Inc. (IPSC) President and CEO insider purchase was reported on a Form 4. The reporting person, who is also a director, bought 35,000 shares of Century Therapeutics common stock on 11/19/2025 at a weighted average price of $0.4951 per share. Following this open-market purchase, the insider beneficially owns 3,271,453 shares, held directly. The filing notes that all profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements, and the price reflects multiple trades between $0.488 and $0.5005 per share.

Century Therapeutics, Inc. (IPSC) reported an insider transaction by its President and CEO, who is also a director of the company. On 11/17/2025, the reporting person sold 32,456 shares of common stock at a price of $0.454 per share.

According to the explanation provided, these sales represent shares sold to cover tax withholding obligations arising from the vesting of restricted stock units and were described as automatic, not at the discretion of the reporting person. After this transaction, the reporting person beneficially owned 3,236,453 shares of Century Therapeutics common stock, held directly.

Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.

The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.